SAFETY AND EFFICACY AT 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TDF USE

被引：0

作者：

Buti, Maria ^{[1
,2
]}

Lampertico, Pietro ^{[3
]}

Lim, Young-Suk ^{[4
]}

Agarwal, Kosh ^{[5
]}

Fung, Scott K. ^{[6
]}

Tsang, Owen ^{[7
]}

Elkhashab, Magdy ^{[8
]}

Kao, Jia-Horng ^{[9
]}

Luis Calleja, Jose ^{[10
]}

Khalili, Mandana ^{[11
]}

Ravendhran, Natarajan ^{[12
]}

Tan, Susanna ^{[13
]}

Flaherty, John F. ^{[13
]}

Gaggar, Anuj ^{[13
]}

Lau, Audrey H. ^{[13
]}

Wu, George ^{[13
]}

Hann, Hie-Won L. ^{[14
]}

Pan, Calvin ^{[15
]}

Kim, Hyung Joon ^{[16
]}

Kennedy, Patrick T. F. ^{[17
]}

Chan, Henry Lik Yuen ^{[18
]}

机构：

[1] Hosp Gen Univ Valle Hebron, Barcelona, Spain

[2] Ciberehd, Barcelona, Spain

[3] Univ Milan, Gastroenterol & Hepatol, Fdn Irccs Ca Granda O Maggiore Policlin, Milan, Italy

[4] Univ Ulsan, Dept Gastroenterol, Ctr Liver, Asan Med Ctr,Coll Med, Ulsan, South Korea

[5] Kings Coll Hosp London, Inst Liver Studies, London, England

[6] Univ Hlth Network, Toronto Gen Hosp, Toronto Ctr Liver Dis, Toronto, ON, Canada

[7] Princess Margaret Hosp, Kwai Chung, 2-10 Princess Margaret Hosp Rd, Hong Kong, Peoples R China

[8] Toronto Liver Ctr, Res, Toronto, ON, Canada

[9] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan

[10] Hosp Univ Puerta De Hierro, Majadahonda, Spain

[11] Univ Calif San Fransisco, San Francisco, CA USA

[12] Digest Dis Associates, Wyomissing, PA USA

[13] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[14] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA

[15] Calvin Q Pan Clin, New York, NY USA

[16] Chung Ang Univ, Coll Med, Seoul, South Korea

[17] Barts Hlth NHS Trust, London, England

[18] Chinese Univ Hong Kong, Hong Kong, Peoples R China

来源：

HEPATOLOGY | 2019年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

476

引用

页码：301A / 301A

页数：1

共 50 条

[31] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) VS TENOFOVIR DISOPROXIL FUMARATE (TDF) IN EAST ASIAN CHRONIC HEPATITIS B PATIENTS FOLLOWING 5-YEARS OF TREATMENT
Wong, Grace Lai Hung
Gane, Edward
Pan, Calvin
Lim, Young-Suk
Fung, Scott
Izumi, Namiki
Ma, Mang
Chan, Carol Yee Kwan
Shalimar, Dr
Buti, Maria
GUT, 2021, 70 : A76 - A76
[32] A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): Week 48 efficacy and safety results
Cheng, W.
Pianko, S.
Thompson, A.
Buti, M.
Gane, E.
Seto, W. K.
Chan, H. L. Y.
Chuang, W-L
Stepanova, T.
Hui, A-J
Lim, Y-S
Mehta, R.
Janssen, H.
Acharya, S. K.
Flaherty, J. F.
Massetto, B.
Cathcart, A.
Dinh, P.
Subramanian, G. M.
Mchutchison, J. G.
Pan, C.
Brunetto, M.
Izumi, N.
Marcellin, P.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 68 - 69
[33] CHRONIC HBV PATIENTS WHO SWITCHED TO TENOFOVIR ALAFENAMIDE (TAF) AFTER EITHER 2 OR 3 YEARS OF PRIOR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT DEMONSTRATED IMPROVEMENT IN BONE AND RENAL SAFETY
Buti, Maria
Izumi, Namiki
Lim, Young-Suk
Janssen, Harry L.
Kao, Jia-Horng
Streinu-Cercel, Adrian
Nurmukhametova, Elena
Ma, Xiaoli
Tabak, Omer
Jablkowski, Maciej
Suri, Vithika
Flaherty, John F.
Lau, Audrey H.
Gaggar, Anuj
Mo, Shuyuan
Chowdhury, Abhijit
Fung, Scott
Chuang, Wan-Long
Gane, Edward
GASTROENTEROLOGY, 2019, 156 (06) : S1195 - S1196
[34] A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results
Lampertico, Pietro
Buti, Maria
Ramji, Alnoor
Fung, Scott
Ahn, Sang Hoon
Chuang, Wan-Long
Yoon, Seung Kew
Kao, Jia-Horng
Chen, Chi-Yi
Tam, Edward
Khalili, Mandana
Bae, Ho
Ma, Xiaoli
Tak, Won Young
Flaherty, John F.
Gaggar, Anuj
Suri, Vithika
Tan, Susanna
Liu, Yang
Wu, George
Subramanian, Mani
Hann, Hie-Won
Agarwal, Kosh
Lim, Young-Suk
Chan, Henry
JOURNAL OF HEPATOLOGY, 2020, 73 : S67 - S68
[35] IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)
Chan, Henry Lik Yuen
Lim, Young-Suk
Seto, Wai Kay
Ning, Qin
Agarwal, Kosh
Janssen, Harry L. A.
Pan, Calvin O.
Chuang, Wan Long
Izumi, Namiki
Fung, Scott
Shalimar
Brunetto, Maurizia
Flaherty, John
Mo, Shuyuan
Cheng, Cong
Lin, Lanjia
Gaggar, Anuj
Subramanian, Mani
Marcellin, Patrick
Gane, Edward
Hou, Jinlin
Buti, Maria
GUT, 2020, 69 : A75 - A76
[36] Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B
Chan, Henry Lik Yuen
Lim, Young-Suk
Seto, Wai Kay Walter
Agarwal, Kosh
Brunetto, Maurizia R.
Janssen, Harry L. A.
Caruntu, Florin
Stepanova, Tatjana
Tsang, Owen
Yatsuhashi, Hiroshi
Tak, Won Young
Chen, Chi-Yi
Celen, Mustafa
Suri, Vithika
Flaherty, John F.
Lin, Lanjia
Cathcart, Andrea
Gaggar, Anuj
Pan, Calvin Q.
Shalimar
Buti, Maria
HEPATOLOGY, 2018, 68 : 227A - 228A
[37] IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB)
Lim, Young-Suk
Chan, Henry Lik Yuen
Seto, Wai-Kay
Ning, Qing
Agarwal, Kosh
Janssen, Harry L. A.
Pan, Calvin Q.
Chuang, Wan Long
Izumi, Namiki
Fung, Scott K.
Shalimar
Brunetto, Maurizia R.
Flaherty, John F.
Mo, Shuyuan
Cheng, Cong
Lin, Lanjia
Gaggar, Anuj
Subramanian, Mani
Marcellin, Patrick
Gane, Edward J.
Hou, Jinlin
Buti, Maria
HEPATOLOGY, 2019, 70 : 126A - 127A
[38] Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-infected, virologically suppressed adults
Raffi, Francois
Orkin, Chloe
Clarke, Amanda
Slama, Laurence
Gallant, Joel
Daar, Eric
Yan, Mingjin
Abram, Michael E.
Friborg, Sandra
Cheng, Andrew
Rhee, Martin
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
[39] Tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) switches: real-world observation of impact on lipid profiles
Banks, T.
Ashton, K.
Ustianowski, A.
Uriel, A.
HIV MEDICINE, 2020, 21 : 56 - 57
[40] ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) RISK PROFILE OF TENOFOVIR ALAFENAMIDE (TAF) VERSUS TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HBV (CHB) PATIENTS UNDER ANTIVIRAL THERAPY FOR 2 YEARS
Fung, Scott K.
Ahn, Sang Hoon
Chen, Chi-Yi
Elkhashab, Magdy
Hann, Hie-Won L.
Jablkowski, Maciej S.
Kim, Yoon Jun
Yurdaydin, Cihan
Peng, Cheng-Yuan
Tuan Nguyen
Yatsuhashi, Hiroshi
Inokuma, Tetsuro
Tan, Susanna K.
Flaherty, John F.
Wang, Hongyuan
Osinusi, Anu O.
Temme, Lauren
Lum, Ernie
Lam, Kelly
Abdurakhmanov, Dzhamal
Lim, Young-Suk
Buti, Maria
HEPATOLOGY, 2021, 74 : 470A - 471A

← 1 2 3 4 5 →